Whole Exome Sequencing (WES) is a targeted next generation sequencing (NGS) approach that focuses on the protein coding regions of the genome—approximately 1–2% of total genomic content, yet home to the vast majority of known disease associated variants. By capturing and sequencing about 180,000 exons, WES provides a cost effective alternative to whole genome sequencing while enabling high depth analysis of genome variants, germline mutations, somatic mutations, and potential pathogenic mechanisms.
WES is widely used across genetic disease research, complex disease studies, cancer genomics, and population genetics, making it a versatile tool for detecting clinically and biologically meaningful variants.
Novogene’s WES service combines extensive experience with multiple commercial exome capture panels, delivering high quality sequencing data, comprehensive bioinformatics analysis, detailed variant annotation, and publication ready figures to support downstream interpretation and scientific discovery.











